SCHEMBL3905409

SCHEMBL3905409

Cc1ccc(C2(N3CCCC3=O)CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
POLB P06746 2/20 0.51
SIGMAR1 Q99720 9/20 0.50
OPRL1 P41146 2/20 0.47
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CXCR3 P49682 1/20 0.45
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
DRD2 P14416 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
HTR2A P28223 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3899843 0.96 LMNA (0.54) LMNAPOLBSIGMAR1OPRL1OPRM1
SCHEMBL3896141 0.87 SIGMAR1 (0.50) LMNAPOLBSIGMAR1OPRL1OPRM1
SCHEMBL27698386 0.87 OPRL1 (0.46) POLBSIGMAR1OPRL1OPRM1OPRD1
SCHEMBL3899999 0.82 OPRL1 (0.45) POLBSIGMAR1OPRL1OPRM1OPRD1
SCHEMBL27698325 0.80 OPRL1 (0.47) POLBSIGMAR1OPRL1OPRM1OPRD1
SCHEMBL3973464 0.80 BACE1 (0.48) POLBSIGMAR1OPRL1OPRM1OPRD1
SCHEMBL6159676 0.77 L3MBTL1 (0.51) LMNAPOLBSIGMAR1OPRL1OPRM1
SCHEMBL4503607 0.75 GRIN1 (0.46) SIGMAR1OPRL1OPRM1OPRD1ALDH1A1
SCHEMBL3902260 0.75 GABRD (0.40) POLBOPRM1KDM4EALDH1A1CYP2C19
SCHEMBL4610609 0.74 CYP3A4 (0.55) LMNAPOLBOPRM1OPRD1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773823-B1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-08-21 EP disclosed
US-7521449-B2 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2009-04-21 US disclosed
US-20070142349-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-06-21 US disclosed
EP-1773823-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-04-18 EP disclosed
WO-2006021654-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142349-A1 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF ADRB3, ADRA2C, OPRK1 LMNA 2618/4885POLB 4026/4885SIGMAR1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.